Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients
Sponsor: Seoul National University Hospital
Listed as NCT01446497, this PHASE4 trial focuses on Normal Tension Glaucoma and remains ongoing. Sponsored by Seoul National University Hospital, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Oct 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .